Inflammatory bowel disease Primair Scleroserende Cholangitis
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Group 1: - Diagnosis of Primary Sclerosing Cholangitis and concommitant diagnosis of Inflammatory bowel disease, Group 2: - Diagnosis of inflammatory bowel disease - 10 patients with routine vedolizumab treatment, 10 patients without vedolizumab treatment , Both groups: - Age 18 years and older, either male or female - Ability to give informed consent - Groups will be stratified for the use of thiopurines - Groups will be stratified for UC, CD and IBDU
Exclusion criteria
Exclusion criteria: - Medical history of proctocolectomy - Use of biologic therapy other than vedolizumab within 8 weeks of enrolment - Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in expression of previously identified potential biomarkers with regard to copy number changes, cancer-relevant gene mutations, methylation status, as well as MIF expression in patients with PSC/IBD versus IBD, stratified by vedolizumab treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| IIa) Evaluation of potential markers in peripheral blood samples in order to evaluate clinical applicability of the potential markers. IIb) Differences between PSC/IBD and IBD in the identified gene alterations. | — |
Countries
Netherlands
Outcome results
None listed